X4 Pharmaceuticals (NASDAQ:XFOR) Stock: Insider Adam Craig Acquires 4,600 Shares

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Chairman Adam Craig bought 4,600 shares of the business’s stock in a transaction dated Friday, October 16th. The shares were bought at an average cost of $2.58 per share, for a total transaction of $11,868.00. Following the transaction, the chairman owned 333,251 shares in the company, valued at approximately $859,787.58. The trade was a 1.40% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

X4 Pharmaceuticals Trading Up 6.2%

NASDAQ:XFOR traded up $0.16 during midday trading on Monday, hitting $2.75. 602,984 shares of the company traded hands, compared to its average volume of 638,974. The firm has a market capitalization of $272.66 million, a P/E ratio of -2.29 and a beta of 0.46. The firm’s fifty day moving average is $3.53 and its 200-day moving average is $3.88. X4 Pharmaceuticals, Inc. has a 12-month low of $2.43 and a 12-month high of $4.83. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. The business had revenue of $8.81 million for the quarter, compared to analysts’ expectations of $2.42 million. On average, sell-side analysts predict that X4 Pharmaceuticals, Inc. will post -0.67 EPS for the current year.

Institutional Trading of X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC grew its holdings in shares of X4 Pharmaceuticals by 6.7% in the first quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock worth $27,826,000 after purchasing an additional 423,196 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in X4 Pharmaceuticals in the 2nd quarter worth about $917,000. Bank of America Corp DE increased its stake in X4 Pharmaceuticals by 321.3% in the 1st quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock worth $622,000 after buying an additional 114,915 shares during the period. Squarepoint Ops LLC purchased a new position in X4 Pharmaceuticals in the 2nd quarter worth about $313,000. Finally, Wellington Management Group LLP bought a new stake in X4 Pharmaceuticals during the 2nd quarter valued at about $242,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Analysts Set New Price Targets

XFOR has been the topic of several analyst reports. Wells Fargo & Company began coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They set an “overweight” rating and a $11.00 price target on the stock. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues.

X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome.